RespireRx Pharmaceuticals Inc (RSPI)

[spyderboi]

Im sure Ive missed the "n" in upcoming 1500mg trial, but I dont know it.

Can anyone instruct me on that? If the "n" is much bigger than in the one reported today then we have room for some ambitious expectations, but if not, Im not convinced that the rectification of the "procedural anomaly" will necessarily provide great expectations of a huge 1500mg result.

The 2100 mg data shown today was Statistically significant, but apparently had rectified the anomaly. The data shown had no error bars (which I always find slightly disturbing) and even at 2100 mg was not "massive".

If one considers that the aim is to allow clinically greater administration of analgesics without incurring RD, Im not overly impressed at a 30% change with a dose that could be considered to be absolutely maximal.

Of course, the dosing was oral and Stoll suggested that i.v. might be more effective, but he also noted that the longer human halflife (compared with rat) should probably reduce the difference between oral and i.v.

The other caveat is whether the Hypercapnic study performed here provides as sensitive a model as clinical opiate depression.

Still overall, while the data today was good (and Id hope would be sufficient for a favorable partnership deal) Im still not convinced that the upcoming 1500mg trial can be expected to yield really impressive data